PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 13, 2022European Urology99 citationsOpen Access

B7-H3 as a Therapeutic Target in Advanced Prostate Cancer

View Full Paper
CGChristina GuoIFInes FigueiredoBGBora Gürel

Key Points

  • This research aims to explore B7-H3 as a potential therapeutic target in advanced prostate cancer.
  • Identified mutations associated with lethal prostate cancers expressing B7-H3.
  • Explored drug binding mechanisms to B7-H3.
  • Discussed implications for patient selection in treatment.
  • Targeting B7-H3 is associated with improved therapeutic outcomes in specific mutation contexts.
  • The presence of B7-H3 assists in selecting suitable patients for novel drug treatments.
  • Developed insights for future drug development focusing on B7-H3.

Abstract

B7-H3, a protein expressed on the surface of the most lethal prostate cancers, in particular those with specific mutations, can be targeted using drugs that bind B7-H3. These findings are relevant for the development of such drugs and for deciding which patients to treat with these new drugs.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Guo et al. (2022) studied this question.

synapsesocial.com/papers/69d776f55f9a1dad53490472https://doi.org/10.1016/j.eururo.2022.09.004
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Metastatic Prostate Cancer2018 · 558 citations
  2. 2B7-H3: A costimulatory molecule for T cell activation and IFN-γ production2001 · 1,030 citations
  3. 3Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation2014 · 586 citations
  4. 4Association of B7‐H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer2022 · 34 citations
  5. 5The contrasting role of B7-H32008 · 208 citations